Volume 21, Number 3—March 2015
CME ACTIVITY - Research
Epidemiology of Human Mycobacterium bovis Disease, California, USA, 2003–2011
Mark Gallivan
, Neha Shah, and Jennifer Flood
, Neha Shah, and Jennifer Flood
Table 3
Multivariate model of sociodemographic and clinical characteristics associated with Mycobacterium bovis disease versus M. tuberculosis disease, California, USA, 2010–2011
| Risk factors | Adjusted odds ratio (95% CI) |
|---|---|
| Diabetes status | |
| Absent | Reference |
| Present |
1.5 (1.1–2.1) |
| Other immunosuppressive condition(s)* | |
| Absent | Reference |
| Present |
1.8 (1.2–2.8) |
| Race/ethnicity | |
| White, non-Hispanic | Reference |
| Black, non-Hispanic | 1.2 (0.2–6.2) |
| Asian, non-Hispanic | 3.6 (1.0–12.8) |
| Hispanic | 7.3 (2.2–24.3) |
| Other |
2.3 (0.2–23.3) |
| Country of birth | |
| United States | Reference |
| Mexico | 1.1 (0.7–1.8) |
| Other |
0.4 (0.2–0.7) |
| Main site of disease | |
| Pulmonary† | Reference |
| Extrapulmonary only | 3.9 (2.8–5.5) |
*Excludes diabetes mellitus and HIV co-infection but includes end-stage renal disease, immunosuppression associated with receiving anti–tumor necrosis factor-α therapy, immunosuppression associated with receiving solid-organ transplant, or other immunosuppressive condition.
†Includes case-patients with pulmonary and extrapulmonary disease.
Page created: February 18, 2015
Page updated: February 18, 2015
Page reviewed: February 18, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.